RxDoctor Payments Data

William Cobell, MD

Gastroenterology · Anaconda, MTNPI 1023281441

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $664 of the $823 with a category attached, or 80.6%. 8 manufacturers reported payments, led by AbbVie at 39.5% of the total. Reporting peaked in 2022 at $337 and has fallen 94.4% since, to $19 in 2025. That places this record below the midpoint for gastroenterology clinicians in MT, where the typical reported total is $823.

$823in general payments, 2019–2025

Across 40 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$325
  • Braintree Laboratories, Inc.$159
  • Takeda Pharmaceuticals U.S.A., Inc.$146
  • Boston Scientific$51
  • Regeneron Healthcare Solutions, Inc.$51
  • Apollo Endosurgery US Inc$43
  • plus $47 from 2 others

What the payments were for

  • Food & beverage$66481%
  • Gifts$15919%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$823 in reported general payments places this provider in the 50th percentile of 34 gastroenterology providers in Montana.

See all gastroenterology providers in Montana

Medicare billing

Part B allowed, 2024
$55,070
Medicare patients
198
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf30$4,936
Cholestyramine LightCholestyramine25$1,881
Omeprazole95$1,785
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl82$1,283
CholestyramineCholestyramine (With Sugar)11$1,009
Pantoprazole Sodium64$792
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl28$460
Dicyclomine Hcl17$347
Ondansetron Hcl92$254
Spironolactone15$169
Famotidine17$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$159$4,93630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 34 gastroenterology providers in Montana.

Other gastroenterology in Anaconda

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →